Skip to main content

Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV.

Publication ,  Journal Article
Kolossváry, M; Sereti, I; Zanni, MV; Fichtenbaum, CJ; Aberg, JA; Bloomfield, GS; Malvestutto, CD; Currier, JS; Chu, SM; Diggs, MR; Lu, AB ...
Published in: J Clin Invest
November 17, 2025

BACKGROUNDStatin therapy lowers the risk of major adverse cardiovascular events (MACE) among people with HIV (PWH). Residual risk pathways contributing to excess MACE beyond LDL-cholesterol (LDL-C) are not well understood. Our objective was to evaluate the association of statin-responsive and other inflammatory and metabolic pathways with MACE in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).METHODSCox proportional hazards models were used to assess the relationship between MACE and proteomics measurements at study entry and year 2, adjusting for time-updated statin use and the baseline 10-year atherosclerotic cardiovascular disease risk score. We built a machine-learning (ML) model to predict MACE using baseline protein values with significant associations.RESULTSFor 765 individuals (age: 50.8 ± 5.9 years, 82% men, 18% women), among 7 proteins changing with statin versus placebo, angiopoietin-related protein 3 (ANGPTL3) related most strongly to MACE (adjusted HR [aHR]: 2.31 per 2-fold-higher levels; 95% CI: 1.11-4.80; P = 0.03), such that lower levels of ANGPTL3 achieved with statin therapy were associated with lower MACE risk. Among 248 proteins that did not change in response to statin therapy, 26 were associated with MACE at a FDR below 0.05. These proteins represented a predominantly humoral immune response, leukocyte chemotaxis, and cytokine pathways. Our proteomics ML model achieved a 10-fold cross-validated concordance index (C-index) of 0.74 ± 0.11 to predict MACE, improving on models using traditional risk prediction scores only (C-index: 0.61 ± 0.18).CONCLUSIONSANGPTL3, as well as key inflammatory pathways, may contribute to a residual risk of MACE among PWH, beyond LDL-C.TRIAL REGISTRATIONClinicalTrials.gov: NCT02344290.FUNDINGNIH, Kowa Pharmaceuticals America, Gilead Sciences, ViiV Healthcare.

Duke Scholars

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

November 17, 2025

Volume

135

Issue

22

Location

United States

Related Subject Headings

  • Middle Aged
  • Male
  • Machine Learning
  • Immunology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • HIV Infections
  • Female
  • Cardiovascular Diseases
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kolossváry, M., Sereti, I., Zanni, M. V., Fichtenbaum, C. J., Aberg, J. A., Bloomfield, G. S., … Grinspoon, S. K. (2025). Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. J Clin Invest, 135(22). https://doi.org/10.1172/JCI196021
Kolossváry, Márton, Irini Sereti, Markella V. Zanni, Carl J. Fichtenbaum, Judith A. Aberg, Gerald S. Bloomfield, Carlos D. Malvestutto, et al. “Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV.J Clin Invest 135, no. 22 (November 17, 2025). https://doi.org/10.1172/JCI196021.
Kolossváry M, Sereti I, Zanni MV, Fichtenbaum CJ, Aberg JA, Bloomfield GS, et al. Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. J Clin Invest. 2025 Nov 17;135(22).
Kolossváry, Márton, et al. “Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV.J Clin Invest, vol. 135, no. 22, Nov. 2025. Pubmed, doi:10.1172/JCI196021.
Kolossváry M, Sereti I, Zanni MV, Fichtenbaum CJ, Aberg JA, Bloomfield GS, Malvestutto CD, Currier JS, Chu SM, Diggs MR, Lu AB, deFilippi C, Foldyna B, McCallum S, Sponseller CA, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. J Clin Invest. 2025 Nov 17;135(22).

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

November 17, 2025

Volume

135

Issue

22

Location

United States

Related Subject Headings

  • Middle Aged
  • Male
  • Machine Learning
  • Immunology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • HIV Infections
  • Female
  • Cardiovascular Diseases
  • Adult